33 preclinical and clinical targets with **STRONG GENETIC SUPPORT**

The industry's largest toolkit with **13** **MODALITIES***

A mix of **INNOVATIVE MOLECULES, NEW INDICATIONS, AND BIOSIMILARS**

A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness. Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects. Human genetic validation is used whenever possible to enhance the likelihood of success.

PHASE ONE

AMG 176 Hematology/ Oncology	AMG 224 Hematology/ Oncology	AMG 330 Hematology/ Oncology
AMG 420 Hematology/ Oncology	AMG 570 Inflammation	AMG 592 Inflammation
AMG 596 Hematology/ Oncology	AMG 598 Cardiovascular	AMG 673 Hematology/ Oncology
AMG 701 Hematology /Oncology	AMG 757 Hematology/ Oncology	AMG 820 Hematology/ Oncology
AMG 966 Inflammation	AMG 986 Cardiovascular	IMLYGIC® (talimogene laherparepvec) Hematology/ Oncology
KYPROLIS® (carfilzomib) Hematology/ Oncology	Oprozomib Hematology/ Oncology	

PHASE TWO

AMG 301 Neuroscience	AMG 557 Inflammation	AMG 714 Inflammation
BLINCYTO® (blinatumomab) Hematology/ Oncology	Tezepelumab Inflammation	

PHASE THREE

AMG 520/ CNP520 Neuroscience	**Aimovig™ (erenumab) Neuroscience	Aranesp® (darbepoetin alfa) Hematology/ Oncology
BLINCYTO® (blinatumomab) Hematology/ Oncology	ENBREL (etanercept) Inflammation	**EVENITY™ (romosozumab) Bone Health
IMLYGIC® (talimogene laherparepvec) Hematology/ Oncology	KYPROLIS® (carfilzomib) Hematology/ Oncology	Omecamtiv mecarbil Cardiovascular
Prolia® (denosumab) Bone Health	Tezepelumab Inflammation	

BIOSIMILARS‡

ABP 494 (biosimilar cetuximab) Hematology/ Oncology	ABP 710 (biosimilar infliximab) Inflammation	ABP 798 (biosimilar rituximab) Hematology/ Oncology & Inflammation	ABP 959 (biosimilar eculizumab) Hematology /Oncology	ABP 980 (biosimilar trastuzumab) Hematology/ Oncology

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.
***Tradename provisionally approved by the United States Food and Drug Administration,*

This information reflects public disclosures current as of February 13, 2018. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE ONE	Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.		
MOLECULE NAME & PRONUNCIATION	**MODALITY**	**THERAPEUTIC AREA**	**DESCRIPTION**
AMG 176	**Small Molecule**	**Hematology/ Oncology**	AMG 176 is a small molecule being investigated as a treatment for multiple myeloma and acute myelogenous leukemia.
AMG 224	**Antibody Drug Conjugate**	**Hematology/ Oncology**	AMG 224 is an antibody drug conjugate being investigated as a treatment for multiple myeloma.
AMG 330	**BiTE® Antibody Construct**	**Hematology/ Oncology**	AMG 330 is an anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated as a treatment for acute myeloid leukemia.
AMG 420	**BiTE® Antibody Construct**	**Hematology/ Oncology**	AMG 420 is an anti-BCMA x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated as a treatment for multiple myeloma.
AMG 570	**Bispecific Antibody**	**Inflammation**	AMG 570 is a bispecific antibody-peptide conjugate that targets BAFF and ICOS ligand. It is being investigated as a treatment for systemic lupus erythematosus. AMG 570 is being developed in collaboration with AstraZeneca plc.
AMG 592	**Fusion Protein**	**Inflammation**	AMG 592 is an IL-2 mutein Fc fusion protein. It is being investigated as a treatment for inflammatory diseases.
AMG 596	**BiTE® Antibody Construct**	**Hematology/ Oncology**	AMG 596 is an anti-EGFRvIII x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated as a treatment for glioblastoma.
AMG 598	**Monoclonal Antibody**	**Cardiovascular**	AMG 598 is a human monoclonal antibody being investigated as a treatment for obesity.
AMG 673	**BiTE® Antibody Construct**	**Hematology/ Oncology**	AMG 673 is an extended half-life anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated as a treatment for relapsed or refractory acute myeloid leukemia.
AMG 701	**BiTE® Antibody Construct**	**Hematology/ Oncology**	AMG 701 is an extended half-life anti-BCMA x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated as a treatment for multiple myeloma.
AMG 757	**BiTE® Antibody Construct**	**Hematology/ Oncology**	AMG 757 is an extended half-life anti-DLL3 x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated as a treatment for small-cell lung cancer.
AMG 820	**Monoclonal Antibody**	**Hematology/ Oncology**	AMG 820 is a human monoclonal antibody that inhibits c-fms and decreases tumor-associated macrophage (TAM) function. It is being investigated as a treatment for various cancer types.
AMG 966	**Monoclonal Antibody**	**Inflammation**	AMG 966 is a monoclonal antibody being investigated for the treatment of inflammatory bowel diseases (crohn's disease and ulcerative colitis).
AMG 986	**Small Molecule**	**Cardiovascular**	AMG 986 is a small molecule agonist of the Apelin receptor (APJ). It is being investigated for the treatment of heart failure.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of February 13, 2018. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE ONE

Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
IMLYGIC® (talimogene laherparepvec) *tal im' oh jeen la her" pa rep' vek*	**Oncolytic Immunotherapy**	**Hematology/ Oncology**	IMLYGIC® is an oncolytic immunotherapy derived from herpes simplex virus type 1 (HSV-1). It is being investigated as a combination treatment with Merck & Company, Inc.'s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with mid- to late-stage metastatic melanoma (Phase 1b/3) and in other cancer types (Phase 1).
KYPROLIS® (carfilzomib) *car fil' zoe mib*	**Small Molecule**	**Hematology/ Oncology**	KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma (Phase 3) and as a treatment for small-cell lung cancer (Phase 1b/2). In January 2018, Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® to include updated overall survival data from the phase 3 head-to-head ENDEAVOR study in patients with relapsed or refractory multiple myeloma. In December 2017, Amgen submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) to include the overall survival data from the ASPIRE study in the product label.
Oprozomib *oh proz' oh mib*	**Small Molecule**	**Hematology/ Oncology**	Oprozomib is an oral proteasome inhibitor. It is being investigated for the treatment of multiple myeloma.

PHASE TWO

Phase 2 clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
AMG 301	**Monoclonal Antibody**	**Neuroscience**	AMG 301 is a human monoclonal antibody that inhibits the pituitary adenylate cyclase-activating polypeptide type 1 (PAC1) receptor. It is being investigated for migraine prevention. AMG 301 is being developed in collaboration with Novartis Pharma AG.
AMG 557	**Monoclonal Antibody**	**Inflammation**	AMG 557 is a human monoclonal antibody that inhibits the action of the ICOS ligand. It is being investigated as a treatment for primary Sjögren's syndrome. AMG 557 is being developed in collaboration with AstraZeneca plc.
AMG 714	**Monoclonal Antibody**	**Inflammation**	AMG 714 is a human monoclonal antibody that binds to Interleukin-15 (IL-15). It is being investigated for the treatment of celiac disease. In November 2017, Amgen reacquired the AMG 714 program from Celimmune LLC.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of February 13, 2018. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

BLINCYTO® (blinatumomab) *blin" a toom' oh mab*	**BiTE® Antibody Construct**	**Hematology/ Oncology**	BLINCYTO® is an anti-CD19 x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated as a treatment for acute lymphoblastic leukemia (ALL) (Phase3) and for adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) (Phase 2/3). In February 2018, Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a label variation for BLINCYTO® to include overall survival data from the phase 3 TOWER study supporting the conversion of the conditional marketing authorization to a full marketing authorization in adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL. In December 2017, Amgen announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the Supplemental Biologics License Application (sBLA) for the treatment of minimal residual disease in patients with ALL. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2018. BLINCYTO® is being developed in Japan by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.
Tezepelumab	**Monoclonal Antibody**	**Inflammation**	Tezepelumab is a human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). It is being investigated as a treatment for asthma (Phase 3) and atopic dermatitis (Phase 2). Tezepelumab is being developed in collaboration with AstraZeneca plc.

PHASE THREE

Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study; typically performed with registrational intent.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
AMG 520/CNP520	**Small Molecule**	**Neuroscience**	AMG 520 (CNP520) is a small molecule inhibitor of beta-site amyloid precursor protein (APP) cleaving enzyme-1 (BACE). It is being investigated for the prevention of Alzheimer's Disease. AMG 520 (CNP520) is being developed in collaboration with Novartis Pharma AG.
Aimovig™ (erenumab)	**Monoclonal Antibody**	**Neuroscience**	Aimovig™ is a human monoclonal antibody that inhibits the receptor for calcitonin gene-related peptide. It is being investigated for the prevention of migraine. In July 2017, Amgen announced that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for Aimovig™ for the prevention of migraine in patients experiencing four or more migraine days per month. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 17, 2018. Aimovig™ is being developed in collaboration with Novartis Pharma AG.
Aranesp® (darbepoetin alfa) *dar" be poe' e tin al fa*	**Therapeutic Protein**	**Hematology/ Oncology**	Aranesp® is a recombinant human protein agonist of the erythropoietin receptor. It is being investigated as a treatment for low risk myelodysplastic syndromes.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of February 13, 2018. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

BLINCYTO® (blinatumomab) *blin" a toom' oh mab*	**BiTE® Antibody Construct**	**Hematology/ Oncology**	BLINCYTO® is an anti-CD19 x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated as a treatment for acute lymphoblastic leukemia (ALL) (Phase 3) and for adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) (Phase 2/3). In February 2018, Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a label variation for BLINCYTO® to include overall survival data from the phase 3 TOWER study supporting the conversion of the conditional marketing authorization to a full marketing authorization in adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL. In December 2017, Amgen announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the Supplemental Biologics License Application (sBLA) for the treatment of minimal residual disease in patients with ALL. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2018. BLINCYTO® is being developed in Japan by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.
ENBREL (etanercept)	**Fusion Protein**	**Inflammation**	ENBREL is a fusion protein that inhibits tumor necrosis factor. It is being investigated as a monotherapy for psoriatic arthritis treatment and as a monotherapy in maintaining remission of rheumatoid arthritis.
EVENTIY™ (romosozumab) *roe" moe soz' ue mab*	**Monoclonal Antibody**	**Bone Health**	EVENITY™ is a humanized monoclonal antibody that inhibits the action of sclerostin. It is being investigated as a treatment for postmenopausal osteoporosis and male osteoporosis. In January 2018, Amgen and UCB announced that the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for EVENITY™ for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In July 2017, Amgen and UCB announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for the Biologics License Application (BLA) for EVENITY™ as a treatment for postmenopausal women with osteoporosis. The resubmission will include data from the Phase 3 ARCH study and select data from the Phase 3 BRIDGE study evaluating EVENITY™ in men with osteoporosis, in addition to the Phase 3 FRAME study. We are currently evaluating all EVENITY™ data and will be working in close collaboration with the FDA. EVENITY™ is being developed in collaboration with UCB. EVENITY™ is being developed in Japan by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.
IMLYGIC® (talimogene laherparepvec) *tal im' oh jeen la her" pa rep' vek*	**Oncolytic Immunotherapy**	**Hematology/ Oncology**	IMLYGIC® is an oncolytic immunotherapy derived from herpes simplex virus type 1 (HSV-1). It is being investigated as a combination treatment with Merck & Company, Inc.'s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with mid- to late-stage metastatic melanoma (Phase 1b/3) and in other cancer types (Phase 1).

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of February 13, 2018. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

KYPROLIS® (carfilzomib) *car fil' zoe mib*	**Small Molecule**	**Hematology/ Oncology**	KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma (Phase 3) and as a treatment for small-cell lung cancer (Phase 1b/2). In January 2018, Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® to include updated overall survival data from the Phase 3 head-to-head ENDEAVOR study in patients with relapsed or refractory multiple myeloma. In December 2017, Amgen submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) to include the overall survival data from the ASPIRE study in the product label.
Omecamtiv mecarbil *om" e kam' tiv me kar' bil*	**Small Molecule**	**Cardiovascular**	Omecamtiv mecarbil is a small molecule activator of cardiac myosin. It is being investigated for the treatment of chronic heart failure. Omecamtiv mecarbil is being developed by Amgen in collaboration with Cytokinetics, Inc. and in collaboration with Servier for certain territories.
Prolia® (denosumab) *den oh sue' mab*	**Monoclonal Antibody**	**Bone Health**	Prolia® is a human monoclonal antibody that inhibits RANKL. It is being investigated for the treatment of glucocorticoid-induced osteoporosis. In October 2017, Amgen announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental Biologics License Application (sBLA) for Prolia® for the treatment of patients with glucocorticoid-induced osteoporosis. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 28, 2018.
Tezepelumab	**Monoclonal Antibody**	**Inflammation**	Tezepelumab is a human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). It is being investigated as a treatment for asthma (Phase 3) and atopic dermatitis (Phase 2). Tezepelumab is being developed in collaboration with AstraZeneca plc.

BIOSIMILARS

A biosimilar, or follow-on biologic, is a biologic medicine designed to have active properties similar to one that has previously been licensed. Biosimilars follow a different regulatory review pathway than innovative products and indications.

MOLECULE NAME	MODALITY	THERAPEUTIC AREA	DESCRIPTION
ABP 494 (biosimilar cetuximab)	**Monoclonal Antibody**	**Hematology/ Oncology**	ABP 494 (biosimilar cetuximab) is an anti-epidermal growth factor receptor (anti-EGFr) monoclonal antibody. It is in pre-clinical development. The reference product primary conditions are colorectal cancer and head and neck cancer. Amgen is developing ABP 494 in collaboration with Allergan.
ABP 710 (biosimilar infliximab)	**Monoclonal Antibody**	**Inflammation**	ABP 710 (biosimilar infliximab) is an anti-tumor necrosis factor-alpha (anti-TNF) monoclonal antibody. The reference product primary conditions are rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, psoriatic arthritis and ankylosing spondylitis.
ABP 798 (biosimilar rituximab)	**Monoclonal Antibody**	**Hematology/ Oncology & Inflammation**	ABP 798 (biosimilar rituximab) is an anti-CD20 monoclonal antibody. The reference product primary conditions are non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis. Amgen is developing ABP 798 in collaboration with Allergan.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of February 13, 2018. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

BIOSIMILARS

A biosimilar, or follow-on biologic, is a biologic medicine designed to have active properties similar to one that has previously been licensed. Biosimilars follow a different regulatory review pathway than innovative products and indications.

MOLECULE NAME	MODALITY	THERAPEUTIC AREA	DESCRIPTION
ABP 959 (biosimilar eculizumab)	**Monoclonal Antibody**	**Hematology/ Oncology**	ABP 959 (biosimilar eculizumab) is a monoclonal antibody that specifically binds to the complement protein C5. The reference product primary conditions are Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS).
ABP 980 (biosimilar trastuzumab)	**Monoclonal Antibody**	**Hematology/ Oncology**	ABP 980 (biosimilar trastuzumab) is an anti-HER2 monoclonal antibody. The reference product primary conditions are HER2+ breast cancer and HER2+ gastric cancer. In July 2017, Amgen and Allergan announced that they submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 980.The FDA has set a Biosimilar User Fee Act target action date of May 28, 2018. In March 2017, Amgen announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA). Amgen is developing ABP 980 in collaboration with Allergan.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of February 13, 2018. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.